◀ Back to MTOR

MTOR — PTBP2

Text-mined interactions from Literome

Wang et al., J Clin Invest 2013 : Rapamycin, an mTOR inhibitor used clinically to suppress T cell responses, also acts on DCs , rendering them tolerogenic
Pan et al., J Immunol 2013 : Its deficiency in DCs results in increased mammalian target of rapamycin (mTOR) complex 1 but decreased mTORC2 signaling, altered cytokine production, impaired CIITA/MHC-II expression, and defective Ag presentation to CD4 T cells after TLR4 stimulation